• Prostatype Genomics opened exercise for TO6 warrants issued in the July 2026 unit rights issue, running through Sept. 15.
• Each TO6 subscribes for 1 new share at SEK 0.1; full exercise would raise about SEK 12.5 million before costs.
• Secured subscriptions, top-down underwriting, letters of intent total about SEK 8.7 million, covering roughly 70% of the maximum.
• Full exercise would issue 125,225,546 shares, increasing the share count to 685,317,051; dilution about 18.3%.
• Last trading day for PROGEN TO6 is Sept. 11; outcome publication planned for Sept. 16.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prostatype Genomics AB published the original content used to generate this news brief on September 01, 2026, and is solely responsible for the information contained therein.